Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone
problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a
newer HIV medication, will improve vascular function and tests of bone health.